Latest Regulatory News

Proteomics International will take Promarker D and Promarker Eso nationwide through Healius from 26 October, extending its first commercial release beyond Western Australia and the Northern Territory. The tests will initially be offered privately at $495 and $997, while revenue remains too uncertain to forecast.

Peet delivered record FY26 earnings as its proposed sale to Ingenia moves through the approval process. Profit rose 77% to $103.4 million, while contracts on hand climbed to $850.7 million and the fully franked dividend increased to 13 cents per share.

Bhagwan Marine reported $81.3 million in Q1 FY27 revenue, up 32% on the prior corresponding period, as subsea services and Riverside Industrial Sands led a stronger start to the year. Recurring revenue also increased to 64%, while new subsea awards and a Riverside Guardian contract added to the growth pipeline.

Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.

Celsius Resources has cleared several hurdles to sell its 95% Opuwo cobalt-copper interest to Chinalco for US$15 million, but regulatory approvals are still outstanding. In the Philippines, criminal, regulatory, court and arbitration proceedings continue to cloud the company’s position in the Makilala project.

Mineral Resources has maintained FY27 guidance after a record quarter for mining services and lithium sales, while Onslow Iron delivered its strongest export month yet. The gains came with a sharp fall in lithium prices, elevated Mt Marion costs and a leadership change in the lithium division.

Energy Resources of Australia has pushed back its critical Pit 3 capping schedule by about 14 months and flagged a potential A$25 million to A$95 million increase in Ranger rehabilitation costs. The warning comes as ERA burns A$62.3 million in quarterly operating cash and awaits a November appeal hearing over Rio Tinto’s compulsory acquisition.

Strike Resources swung to an $8.58 million FY2026 profit, largely through its stake in LE Minerals rather than iron ore operations. The company is also relying on a conditional Apurimac sale for cash while withdrawing its previously reported mineral resource estimate.

Bulletin Resources has shifted its exploration focus further towards Lake Rebecca after reporting a $569,632 loss for the year, with Chifley drilling pointing to a possible concealed gold source but stopping well short of a discovery. The company ended June with $13.5 million in cash and listed investments, although its exploration portfolio still carries permitting and funding risks.

Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.

TradeWindow has signed a 12-month agreement to provide its Prodoc export documentation software across Lactalis’ Australian and New Zealand operations. The contract is described as being of significant value, although its financial contribution remains undisclosed.

Minbos Resources spent A$4.7 million on plant and equipment as construction advanced at its Cabinda phosphate project in Angola. The company also completed a post-quarter A$6 million placement, but BFA funding and approvals remain key dependencies for its Q2 2027 commissioning target.